Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 20,635 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood Clear all
Terminated Phase 2 Interventional Results available

PR3-AAV Resilient Remission or PRRR

NCT05376319
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
Interventions
Obinutuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Enrolling by invitation Not applicable Interventional

The T1D Talks Pilot Study

NCT07109128
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
The T1D Talks: A Virtual Group for Teens and Tweens with T1D
Behavioral
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
12 Years to 14 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Muscle Energy Metabolism and Metabolic Flexibility in Older Men and Women

NCT03701867
View directory record Official record
Conditions
Energy Metabolism
Interventions
Metabolic Flexibility Tests
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 20, 2026, 10:49 PM EDT
Terminated Not applicable Interventional

Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy

NCT01850771
View directory record Official record
Conditions
Radiculopathy, Herniated Disc, Disc Degeneration
Interventions
Regenexx PL-Disc, Steroid Epidural
Procedure
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 20, 2026, 10:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes

NCT02693964
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Bone density and carotid ultrasound
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109
View directory record Official record
Conditions
Metabolic Diseases
Interventions
Oral Glucose Tolerance Test, Kisspeptin, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Not listed Phase 2 Interventional

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698
View directory record Official record
Conditions
Breast Cancer, Renal Cell Carcinoma
Interventions
IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 20, 2026, 10:49 PM EDT
Active, not recruiting Phase 1 Interventional

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

NCT02496663
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

NCT03179163
View directory record Official record
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 20, 2026, 10:49 PM EDT
Recruiting Phase 1 Interventional

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

NCT04640987
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback
Biological · Device · Drug
Lead sponsor
Porteus, Matthew, MD
Other
Eligibility
1 Month to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

NCT00880321
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Mechanisms of Exercise Behavior Change

NCT03465800
View directory record Official record
Conditions
Overweight and Obesity, Physical Activity, Incentives
Interventions
self-monitoring, daily incentives, delayed lump sum incentives
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 20, 2026, 10:49 PM EDT
Suspended Phase 1 Interventional

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00077493
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy, monoclonal antibody therapy
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 24 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Not applicable Interventional

Use of Blood Flow Restriction (BFR) Therapy in Post-operative Rehabilitation Following Distal Biceps Tendon Repair

NCT04503421
View directory record Official record
Conditions
Bicep Tendon Rupture
Interventions
Blood Flow Restriction Therapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin

NCT02141906
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Oncozene-DEB-TACE
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiac Rehab Effects in HFpEF

NCT04506606
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Afferent block
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Not applicable Interventional Results available

The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass

NCT01435304
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
method of returning residual CPB blood ( Hemobag®)
Device
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 20, 2026, 10:49 PM EDT
Not listed No phase listed Observational

Markers of Oxidative Stress Diastolic Dysfunction

NCT00846404
View directory record Official record
Conditions
Diastolic Heart Failure, Diastolic Dysfunction
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 20, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

NCT03326752
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
Drug · Device
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 20, 2026, 10:49 PM EDT
Terminated No phase listed Observational

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

NCT02549638
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Squamous, Squamous Cell Carcinoma, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions
DNA Extraction
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 10:49 PM EDT